Analyst Ami Fadia of Needham maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), boosting the price target to $210.00.
Ami Fadia has given his Buy rating due to a combination of factors that suggest a positive outlook for Jazz Pharmaceuticals. The company has successfully reached a settlement with all ANDA filers regarding Epidiolex, securing its market entry until the very late 2030s, which is a significant strategic win. Additionally, the delay in the readout of Zani’s GEA trial to the second half of 2025, due to a slower than expected event rate, might be interpreted as a positive sign.
Furthermore, management’s comments on the sustainability of Xywav, the stabilization of Rylaze, and the potential to extend Zepzelca’s intellectual property are promising. The 2025 financial guidance provided by the management aligns with consensus expectations, with revenue projections at the midpoint of $4,275 million. The research and development expenses are projected to be approximately 15% below expectations, which is favorable. These factors combined have led to an updated price target of $210, reflecting confidence in the company’s future performance.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $190.00 price target.